Adlai Nortye (ANL) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
24 Apr, 2026Management team and governance
Executive officers are employed under fixed-term agreements with provisions for termination for cause or without cause with severance.
Executive officers are bound by confidentiality, invention assignment, non-competition, and non-solicitation clauses during and after employment.
Directors and executive officers are indemnified against certain liabilities and expenses related to their roles.
Board as of April 2026 includes Yang Lu (CEO/Chairman), Xiaofeng (Alex) Ye (CFO), and five other directors, including independent directors.
Offering details and pricing
Registration statement covers up to $600,000,000 in securities to be issued and sold from time to time.
Includes offer and resale by selling securityholders of up to 98,577,627 Class A Ordinary Shares.
Securities may include Class A ordinary shares (including ADSs), debt securities, warrants, subscription rights, and units.
Risk factors and disclosures
Indemnification for directors and officers may be limited by public policy and subject to court adjudication.
Shares are non-assessable, but exceptions exist in cases of fraud or improper purpose.
Company must comply with Cayman Islands sanctions and maintain good standing through annual filings.
Latest events from Adlai Nortye
- Global oncology innovator offers $600M in securities, advancing RAS and immunotherapy pipeline.ANL
Registration filing23 Apr 2026 - 2025 net loss narrowed, R&D costs fell, and new PIPE and licensing deals boosted liquidity.ANL
Q4 202510 Apr 2026 - Shelf registration enables up to $600M equity offering to fund oncology R&D and growth.ANL
Registration Filing10 Mar 2026 - Net loss improved to $51.9M in 2024; cash $60.9M; AN2025 Phase III topline data due Q2 2025.ANL
Q4 20249 Oct 2025 - AN0025 plus chemoradiotherapy achieved high response and disease control rates with good tolerability.ANL
Investor Presentation3 Jul 2025 - AN4005 demonstrated promising safety and efficacy signals in advanced solid tumors.ANL
Investor Presentation3 Jul 2025 - Tri-specific AN8025 delivers coordinated immune stimulation and strong preclinical anti-tumor efficacy.ANL
Investor Presentation3 Jul 2025 - AN9025 delivers potent, sustained anti-tumor effects in RAS-mutant models and is IND-enabling.ANL
Investor Presentation3 Jul 2025 - Multiple first-in-class oncology assets show strong preclinical and early clinical promise.ANL
Corporate Presentation3 Jul 2025